Evaluation of [18F]FET PET for the Detection of ACTH-Secreting Corticotroph Pituitary Neuroendocrine Tumors

What this Trial Is About

Cushing's disease is caused by tumors in the pituitary gland that produce excess adrenocorticotropic hormone (ACTH). This research is evaluating whether a special type of imaging called positron emission tomography (PET) using [18F]fluoroethyl-L-tyrosine ([18F]FET) can better locate these small tumors compared to the usual magnetic resonance imaging (MRI). The study aims to see if this new imaging helps surgical planning and reduces the need for invasive tests, using surgical tissue analysis as the gold standard for comparison. The study observes adults with confirmed Cushing's disease who have unclear or small tumors on MRI and who underwent [18F]FET PET scans as part of their care. It analyzes existing imaging data, MRI results, and routine blood tests without adding new procedures. The research also looks at how often PET changes tumor localization compared to MRI, agreement between doctors reading the PET scans, and links between PET signals and hormone levels. Participants are adults with biochemical confirmation of Cushing's disease and MRI scans showing no or small tumors. Researchers will review medical imaging and hormone test results collected during regular care. The main measure is how well [18F]FET PET identifies tumors within three months. Additional assessments include comparing PET and MRI results, consistency between scan readers, and the relationship between PET findings and disease remission. The study began in November 2023 and follows participants through analyses completed within three months.

Evaluation of Positron Emission Tomography (PET) With [18F]FET for the Detection of ACTH-Secreting Corticotroph Pituitary Neuroendocrine Tumors.